These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34051065)

  • 1. Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVID-19.
    Blach S; Blomé M; Duberg AS; Jerkeman A; Kåberg M; Klasa PE; Lagging M; Razavi-Shearer D; Razavi H; Aleman S
    Liver Int; 2021 Sep; 41(9):2024-2031. PubMed ID: 34051065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model.
    Heffernan A; Cooke GS; Nayagam S; Thursz M; Hallett TB
    Lancet; 2019 Mar; 393(10178):1319-1329. PubMed ID: 30704789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
    Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
    J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Public health interventions, priority populations, and the impact of COVID-19 disruptions on hepatitis C elimination among people who have injected drugs in Montreal (Canada): A modeling study.
    Lanièce Delaunay C; Klein MB; Godin A; Cox J; Kronfli N; Lebouché B; Doyle C; Maheu-Giroux M
    Int J Drug Policy; 2023 Jun; 116():104026. PubMed ID: 37075626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can hepatitis C elimination targets be sustained among people who inject drugs post-2030?
    Lanièce Delaunay C; Godin A; Kronfli N; Panagiotoglou D; Cox J; Alary M; Klein MB; Maheu-Giroux M
    Int J Drug Policy; 2021 Oct; 96():103343. PubMed ID: 34215459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leveraging opportunities for treatment/user simplicity (LOTUS): Navigating the current treatment landscape for achieving hepatitis C virus elimination among persons who inject drugs.
    Sulkowski MS; Martinez A; Tyson GL; Scholz K; Franco RA; Kohli A; Julius SF; Deming P; Fink SA; Lynch K; Roytman M; Stainbrook TR; Turner MD; Viera-Briggs M; Ramers CB
    J Viral Hepat; 2024 Jun; 31(6):342-356. PubMed ID: 38433561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral hepatitis C pandemic: Challenges and threats to its elimination.
    Krekulova L; Honzák R; Riley LW
    J Viral Hepat; 2021 May; 28(5):694-698. PubMed ID: 33550694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of prison-based interventions for hepatitis C virus (HCV) micro-elimination among people who inject drugs in Montréal, Canada.
    Godin A; Kronfli N; Cox J; Alary M; Maheu-Giroux M
    Int J Drug Policy; 2021 Feb; 88():102738. PubMed ID: 32278651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries.
    Maticic M; Pirnat Z; Leicht A; Zimmermann R; Windelinck T; Jauffret-Roustide M; Duffell E; Tammi T; Schatz E
    Harm Reduct J; 2020 Nov; 17(1):89. PubMed ID: 33213481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Planning the hepatitis C virus elimination in Cyprus: A modeling study.
    Gountas I; Yiasemi I; Kyprianou E; Mina C; Georgiou C; Katsioloudes P; Kouroufexi A; Demetriou A; Xenofontos E; Nikolopoulos G
    World J Gastroenterol; 2021 Aug; 27(31):5219-5231. PubMed ID: 34497446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?
    Gountas I; Sypsa V; Anagnostou O; Martin N; Vickerman P; Kafetzopoulos E; Hatzakis A
    Addiction; 2017 Jul; 112(7):1290-1299. PubMed ID: 28107585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scaling-up HCV prevention and treatment interventions in rural United States-model projections for tackling an increasing epidemic.
    Fraser H; Zibbell J; Hoerger T; Hariri S; Vellozzi C; Martin NK; Kral AH; Hickman M; Ward JW; Vickerman P
    Addiction; 2018 Jan; 113(1):173-182. PubMed ID: 28734093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany.
    Tergast TL; Blach S; Tacke F; Berg T; Cornberg M; Kautz A; Manns M; Razavi H; Sarrazin C; Serfert Y; van Thiel I; Zeuzem S; Wedemeyer H
    J Viral Hepat; 2022 Jul; 29(7):536-542. PubMed ID: 35357770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
    Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Mabileau G; Dhersin JS; Yazdanpanah Y
    J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling Hepatitis C Elimination Among People Who Inject Drugs in New Hampshire.
    Blake A; Smith JE
    JAMA Netw Open; 2021 Aug; 4(8):e2119092. PubMed ID: 34342652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.
    Scott N; Doyle JS; Wilson DP; Wade A; Howell J; Pedrana A; Thompson A; Hellard ME
    Int J Drug Policy; 2017 Sep; 47():107-116. PubMed ID: 28797497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030.
    Bruggmann P; Blach S; Deltenre P; Fehr J; Kouyos R; Lavanchy D; Müllhaupt B; Rauch A; Razavi H; Schmid P; Semela D; Stoeckle M; Negro F
    Swiss Med Wkly; 2017; 147():w14543. PubMed ID: 29120012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland.
    Fraser H; Mukandavire C; Martin NK; Goldberg D; Palmateer N; Munro A; Taylor A; Hickman M; Hutchinson S; Vickerman P
    Addiction; 2018 Nov; 113(11):2118-2131. PubMed ID: 29781207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
    Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
    Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland.
    Stone J; Martin NK; Hickman M; Hutchinson SJ; Aspinall E; Taylor A; Munro A; Dunleavy K; Peters E; Bramley P; Hayes PC; Goldberg DJ; Vickerman P
    Addiction; 2017 Jul; 112(7):1302-1314. PubMed ID: 28257600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.